MX2021013844A - Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. - Google Patents
Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos.Info
- Publication number
- MX2021013844A MX2021013844A MX2021013844A MX2021013844A MX2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A MX 2021013844 A MX2021013844 A MX 2021013844A
- Authority
- MX
- Mexico
- Prior art keywords
- activable
- linker
- variant
- human immunoglobulin
- hinge region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906685.1A GB201906685D0 (en) | 2019-05-13 | 2019-05-13 | Activatable protein constructs and uses thereof |
| GBGB1910254.0A GB201910254D0 (en) | 2019-05-13 | 2019-07-17 | Activatable protein constructs and uses thereof |
| GBGB1917678.3A GB201917678D0 (en) | 2019-05-13 | 2019-12-04 | Activatable protein constructs and uses thereof |
| GBGB2001196.1A GB202001196D0 (en) | 2019-05-13 | 2020-01-28 | Activatable protein constructs and uses thereof |
| PCT/EP2020/063362 WO2020229553A1 (en) | 2019-05-13 | 2020-05-13 | Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013844A true MX2021013844A (es) | 2022-03-17 |
Family
ID=67384589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013844A MX2021013844A (es) | 2019-05-13 | 2020-05-13 | Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230192899A1 (https=) |
| EP (1) | EP3969116A1 (https=) |
| JP (2) | JP7617027B2 (https=) |
| KR (1) | KR20220008841A (https=) |
| CN (2) | CN113840634B (https=) |
| AU (1) | AU2020276891A1 (https=) |
| BR (1) | BR112021022661A2 (https=) |
| CA (1) | CA3138827A1 (https=) |
| GB (4) | GB201906685D0 (https=) |
| IL (1) | IL287890A (https=) |
| MX (1) | MX2021013844A (https=) |
| SG (1) | SG11202112114YA (https=) |
| WO (1) | WO2020229553A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| EP4034171A1 (en) * | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| JP2023547499A (ja) * | 2020-11-06 | 2023-11-10 | ノバルティス アーゲー | 抗体Ｆｃ変異体 |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023144423A1 (en) * | 2022-01-31 | 2023-08-03 | LockBody Therapeutics Ltd | Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof |
| CA3246893A1 (en) * | 2022-03-30 | 2023-10-05 | Centessa Pharmaceuticals (Uk) Limited | Activable Bispecific Anti-CD3 and Anti-PD-L1 Proteins and Their Uses |
| WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| CA3251998A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
| GB202302074D0 (en) * | 2023-02-14 | 2023-03-29 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2024218512A1 (en) * | 2023-04-19 | 2024-10-24 | Centessa Pharmaceuticals (Uk) Limited | Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof |
| WO2024218509A1 (en) * | 2023-04-19 | 2024-10-24 | Centessa Pharmaceuticals (Uk) Limited | Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof |
| KR20250088543A (ko) * | 2023-05-19 | 2025-06-17 | 서울대학교산학협력단 | Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포 |
| CN121866269A (zh) * | 2023-09-14 | 2026-04-14 | Abl生物公司 | 通过施用抗pd-l1/抗4-1bb双特异性抗体治疗癌症的方法 |
| WO2026038050A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038047A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
| WO2026038048A2 (en) * | 2024-08-14 | 2026-02-19 | Creasallis Ltd | Agents, methods and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2352763T5 (pl) * | 2008-10-01 | 2023-01-30 | Amgen Research (Munich) Gmbh | Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
| KR102499191B1 (ko) * | 2016-03-18 | 2023-02-13 | 프레드 허친슨 캔서 센터 | Cd20 면역요법을 위한 조성물 및 방법 |
| CR20180453A (es) * | 2016-03-22 | 2018-12-05 | Hoffmann La Roche | Moleculas biespecíficas de células t activadas por proteasas |
| AU2018250641B2 (en) * | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| EP3668897B1 (en) | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
-
2019
- 2019-05-13 GB GBGB1906685.1A patent/GB201906685D0/en not_active Ceased
- 2019-07-17 GB GBGB1910254.0A patent/GB201910254D0/en not_active Ceased
- 2019-12-04 GB GBGB1917678.3A patent/GB201917678D0/en not_active Ceased
-
2020
- 2020-01-28 GB GBGB2001196.1A patent/GB202001196D0/en not_active Ceased
- 2020-05-13 BR BR112021022661A patent/BR112021022661A2/pt unknown
- 2020-05-13 AU AU2020276891A patent/AU2020276891A1/en active Pending
- 2020-05-13 WO PCT/EP2020/063362 patent/WO2020229553A1/en not_active Ceased
- 2020-05-13 KR KR1020217038644A patent/KR20220008841A/ko active Pending
- 2020-05-13 EP EP20726749.3A patent/EP3969116A1/en active Pending
- 2020-05-13 CA CA3138827A patent/CA3138827A1/en active Pending
- 2020-05-13 CN CN202080034818.9A patent/CN113840634B/zh active Active
- 2020-05-13 SG SG11202112114YA patent/SG11202112114YA/en unknown
- 2020-05-13 US US17/610,899 patent/US20230192899A1/en active Pending
- 2020-05-13 MX MX2021013844A patent/MX2021013844A/es unknown
- 2020-05-13 CN CN202510701821.6A patent/CN120554533A/zh active Pending
- 2020-05-13 JP JP2021565875A patent/JP7617027B2/ja active Active
-
2021
- 2021-11-07 IL IL287890A patent/IL287890A/en unknown
-
2025
- 2025-01-06 JP JP2025001728A patent/JP2025039660A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220008841A (ko) | 2022-01-21 |
| GB201906685D0 (en) | 2019-06-26 |
| SG11202112114YA (en) | 2021-11-29 |
| CN113840634B (zh) | 2025-07-08 |
| EP3969116A1 (en) | 2022-03-23 |
| JP2025039660A (ja) | 2025-03-21 |
| GB201910254D0 (en) | 2019-08-28 |
| GB202001196D0 (en) | 2020-03-11 |
| JP2022532534A (ja) | 2022-07-15 |
| BR112021022661A2 (pt) | 2022-03-29 |
| CN113840634A (zh) | 2021-12-24 |
| GB201917678D0 (en) | 2020-01-15 |
| AU2020276891A1 (en) | 2021-12-23 |
| JP7617027B2 (ja) | 2025-01-17 |
| CN120554533A (zh) | 2025-08-29 |
| WO2020229553A1 (en) | 2020-11-19 |
| CA3138827A1 (en) | 2020-11-19 |
| IL287890A (en) | 2022-01-01 |
| US20230192899A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013844A (es) | Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos. | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| CL2024003715A1 (es) | Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso. | |
| PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| BR112022013236A2 (pt) | Anticorpos anti-cd73 e usos dos mesmos | |
| CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
| BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| BR112022012327A2 (pt) | Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
| AR106570A1 (es) | Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos | |
| BR112012009854B8 (pt) | proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma | |
| MX2022001049A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos. | |
| AR069681A1 (es) | Moleculas de union al receptor ox40 humano | |
| BR112019008634A2 (pt) | anticorpos anti-pd-l1 e variantes | |
| AR066198A1 (es) | Anticuerpos anti ige apoptoticos | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| MY199683A (en) | Anti-pd-1 antibodies | |
| BR112013004266A8 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos. | |
| BR112021018608A2 (pt) | Anticorpos para claudina-6 e conjugados de fármaco | |
| BR112012013915A2 (pt) | anticorpos anti-c4. 4a e usos dos mesmos |